Consultation has opened for the March 2024 Pharmaceutical Benefits Advisory Committee (PBAC) agenda. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration. The PBAC considers these public consultation inputs when considering the clinical and economic evidence...
Closes 31 January 2024
Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 4-5 April 2024. MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application. ...
Closes 16 February 2024
The Medical Services Advisory Committee (MSAC) has developed a Draft Framework for the MSAC assessment of radiopharmaceuticals. The purpose of this Framework is to identify the supplementary information requirements to those set out in the Guidelines for preparing assessments for the Medical Services Advisory Committee (“MSAC Guidelines”) to ensure that radiopharmaceuticals to be...
Closed 21 November 2023
Consultation is now open for applications that are anticipated to be considered by the PICO Advisory Sub-Committee (PASC) of the Medical Services Advisory Committee (MSAC) on 7-8 December 2023. PASC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies...
Closed 3 November 2023
Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 23-24 November 2023. MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application. ...
Closed 6 October 2023
Consultation has opened for the November 2023 Pharmaceutical Benefits Advisory Committee (PBAC) agenda. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration. The PBAC considers these public consultation inputs when considering the clinical and economic evidence...
Closed 20 September 2023
Expressions of interest for participating in a deep-dive with the Reference Committee for the HTA Review. Throughout the review the Reference Committee would like to have direct discussions with stakeholders who have in-depth knowledge or understanding on topics or issues highly relevant to the review. These deep-dives will allow the Reference Committee to unpack the more...
Closed 1 September 2023